Upload folder using huggingface_hub

HC_NEU_006_schema.json

@@ -0,0 +1,111 @@
+{
+  "patient_id": "str",
+  "headache_subtype": "str",
+  "sex": "str",
+  "age_at_baseline": "int64",
+  "race_ethnicity": "str",
+  "education_years": "int64",
+  "geographic_region": "str",
+  "bmi": "float64",
+  "obesity_flag": "int64",
+  "anxiety_disorder_flag": "int64",
+  "depression_flag": "int64",
+  "fibromyalgia_flag": "int64",
+  "sleep_disorder_flag": "int64",
+  "hypertension_flag": "int64",
+  "ocp_use_flag": "int64",
+  "psychiatric_medication_flag": "int64",
+  "prior_er_visit_flag": "int64",
+  "headache_specialist_flag": "int64",
+  "headache_days_per_month": "int64",
+  "migraine_days_per_month": "int64",
+  "headache_duration_hours": "float64",
+  "pain_intensity_nrs": "float64",
+  "pain_location": "str",
+  "pain_character": "str",
+  "aggravation_by_activity": "int64",
+  "nausea_flag": "int64",
+  "vomiting_flag": "int64",
+  "photophobia_flag": "int64",
+  "phonophobia_flag": "int64",
+  "osmophobia_flag": "int64",
+  "allodynia_score_asc12": "int64",
+  "cutaneous_allodynia_flag": "int64",
+  "chronification_risk_score": "float64",
+  "prodrome_flag": "int64",
+  "prodrome_duration_hours": "float64",
+  "prodrome_symptoms": "str",
+  "aura_flag": "int64",
+  "aura_type": "str",
+  "aura_duration_minutes": "int64",
+  "visual_aura_subtype": "str",
+  "spreading_depression_proxy": "float64",
+  "postdrome_flag": "int64",
+  "postdrome_duration_hours": "float64",
+  "postdrome_symptoms": "str",
+  "trigger_stress": "int64",
+  "trigger_sleep_disruption": "int64",
+  "trigger_hormonal": "int64",
+  "trigger_weather_barometric": "int64",
+  "trigger_skipped_meals": "int64",
+  "trigger_bright_light": "int64",
+  "trigger_strong_odors": "int64",
+  "trigger_dehydration": "int64",
+  "trigger_alcohol": "int64",
+  "trigger_caffeine_withdrawal": "int64",
+  "trigger_dietary_tyramine": "int64",
+  "trigger_physical_exertion": "int64",
+  "n_triggers_reported": "int64",
+  "trigger_screen_time_hours": "float64",
+  "trigger_reliability_score": "float64",
+  "menstrual_cycle_day": "int64",
+  "perimenstrual_attack_flag": "int64",
+  "acute_treatment_name": "str",
+  "acute_treatment_class": "str",
+  "acute_dose_mg": "int64",
+  "time_to_treat_hours": "float64",
+  "pain_free_2hr_flag": "int64",
+  "pain_relief_2hr_flag": "int64",
+  "most_bothersome_symptom_relief": "int64",
+  "sustained_pain_free_24hr": "int64",
+  "rescue_medication_flag": "int64",
+  "medication_overuse_days": "int64",
+  "medication_overuse_headache_flag": "int64",
+  "treatment_satisfaction_score": "float64",
+  "preventive_medication": "str",
+  "preventive_class": "str",
+  "preventive_dose_mg": "int64",
+  "botox_units": "int64",
+  "preventive_duration_months": "int64",
+  "preventive_adherence_pct": "float64",
+  "monthly_mmd_reduction": "float64",
+  "responder_50pct_flag": "int64",
+  "responder_75pct_flag": "int64",
+  "cgrp_mechanism_flag": "int64",
+  "preventive_discontinuation_flag": "int64",
+  "discontinuation_reason": "str",
+  "midas_score": "int64",
+  "midas_grade": "str",
+  "hit6_score": "int64",
+  "promis_pain_interference_t": "float64",
+  "work_days_lost_per_month": "float64",
+  "presenteeism_days_per_month": "float64",
+  "global_productivity_loss_pct": "float64",
+  "sf12_pcs": "float64",
+  "sf12_mcs": "float64",
+  "phq9_score": "int64",
+  "gad7_score": "int64",
+  "psqi_score": "int64",
+  "caregiver_burden_score": "float64",
+  "healthcare_visits_per_year": "int64",
+  "annual_migraine_cost_usd": "float64",
+  "plasma_cgrp_pg_ml": "float64",
+  "plasma_cgrp_ictal_flag": "int64",
+  "cgrp_response_index": "float64",
+  "plasma_serotonin_ng_ml": "float64",
+  "cortisol_am_ug_dl": "float64",
+  "magnesium_serum_mg_dl": "float64",
+  "magnesium_deficiency_flag": "int64",
+  "inflammatory_index": "float64",
+  "autonomic_dysfunction_score": "float64"
+}

README.md

@@ -0,0 +1,404 @@
+---
+license: cc-by-nc-4.0
+task_categories:
+  - tabular-classification
+  - tabular-regression
+language:
+  - en
+tags:
+  - synthetic
+  - migraine
+  - headache
+  - chronic-migraine
+  - ichd-3
+  - ampp
+  - cameo
+  - cgrp
+  - cgrp-mab
+  - erenumab
+  - fremanezumab
+  - galcanezumab
+  - eptinezumab
+  - atogepant
+  - triptan
+  - sumatriptan
+  - rimegepant
+  - ubrogepant
+  - lasmiditan
+  - aura
+  - midas
+  - hit-6
+  - neurology
+  - clinical-trial
+  - tension-headache
+  - cluster-headache
+  - medication-overuse-headache
+pretty_name: "HC-NEU-006 — Migraine & Chronic Headache Dataset (Sample)"
+size_categories:
+  - 1K<n<10K
+---
+
+# HC-NEU-006 — Migraine & Chronic Headache Dataset (Sample)
+
+A schema-identical preview of **HC-NEU-006**, the XpertSystems.ai
+synthetic **migraine and chronic headache patient cohort** dataset for
+clinical trial research, CGRP-era treatment outcome modeling, ICHD-3
+subtype classification ML, AMPP / CaMEO-comparable headache analytics,
+and migraine-specific machine learning. The full product covers 10,000
+patients; this sample is HF-sized at 3,000 patients.
+
+> **Built by** XpertSystems.ai — Synthetic Data Platform
+> **Contact** [pradeep@xpertsystems.ai](mailto:pradeep@xpertsystems.ai) · [xpertsystems.ai](https://xpertsystems.ai)
+> **License** CC-BY-NC-4.0 (sample); commercial license available for the full product.
+
+---
+
+## What HC-NEU-006 does — and how it grows the Healthcare/Neurology vertical
+
+HC-NEU-006 is the **sixth Healthcare / Neurology SKU** in the
+XpertSystems catalog. After AD, PD, Epilepsy, MS, and Stroke, the
+catalog now extends into **chronic episodic neurology** — diseases
+managed primarily through pharmacological symptom and prevention
+strategies, rather than acute interventional or neuroprotective trials.
+
+| SKU | Disease | US Patients | Annual Pharma R&D | Architecture |
+|---|---|---|---|---|
+| HC-NEU-001 | Alzheimer's | 6.9M | $8B | Single longitudinal |
+| HC-NEU-002 | Parkinson's | 1.0M | $5B | Single longitudinal |
+| HC-NEU-003 | Epilepsy | 3.4M | $3B | Cross-sectional |
+| HC-NEU-004 | Multiple Sclerosis | 1.0M | $6B | Multi-table relational |
+| HC-NEU-005 | Stroke | 7.0M | $3B | Cross-sectional |
+| HC-NEU-006 | **Migraine & Headache** | **39M** | **$5B+** | **Cross-sectional** |
+
+**Migraine is the single largest neurology cohort by patient count** —
+~39M Americans, with ~9M chronic migraine sufferers. The CGRP era
+(Erenumab/Fremanezumab/Galcanezumab/Eptinezumab + Ubrogepant/Rimegepant/
+Atogepant) has transformed migraine treatment over the last 6 years,
+creating a huge market for clinical research and real-world data.
+
+This is the substrate **migraine pharma R&D teams, CGRP-era market
+analytics, headache specialist clinic analytics, and migraine-specific
+ML teams** have been waiting for: a coherent cross-sectional dataset
+where ICHD-3 subtype × triggers × CGRP biomarkers × acute treatments
+× CGRP mAb preventive response × disability outcomes all interact
+with **STRIVE / HALO / EVOLVE / PROMISE-2 trial-grade calibration**.
+
+| Buyer Persona | Use Case |
+|---|---|
+| Migraine Pharma R&D | CGRP mAb comparator modeling, trial design |
+| CGRP-Era Market Analytics | Treatment-switching pattern analytics |
+| Headache Specialist Clinic | AMPP / CaMEO-comparable benchmarking |
+| MIDAS / HIT-6 Modeling | Disability outcome ML training |
+| Trigger-Pattern ML | 13-trigger × headache-day prediction |
+| Pediatric & Cluster Headache | Subtype-specific cohort enrichment |
+| Migraine Digital Therapeutic | Treatment-response wearable ML |
+| Real-World Evidence (RWE) | CGRP mAb adherence + discontinuation analytics |
+| Migraine Genetics | Aura subtype + family history phenotype ML |
+
+---
+
+## What's inside
+
+**Single cross-sectional dataframe**, one row per patient. 9 clinical
+modules concatenated horizontally.
+
+| Output | Rows (sample) | Columns | Size |
+|---|---:|---:|---|
+| `HC_NEU_006_dataset.csv` | 3,000 | 109 | ~1.5 MB |
+
+Schema provided in `HC_NEU_006_schema.json`.
+
+### Module structure (109 columns total)
+
+| Module | Cols | Coverage |
+|---|---:|---|
+| Demographics | 8 | sex, age, race/ethnicity, education, region, BMI |
+| Comorbidities | 10 | obesity, anxiety, depression, fibromyalgia, sleep, HTN, OCP, psych med, ER, specialist |
+| Headache characterization | 15 | subtype, HDM, MDM, duration, pain intensity/location/character, nausea, photophobia, allodynia |
+| Prodrome/aura | 9 | flags, duration, symptoms, aura type, visual aura subtype, postdrome |
+| Triggers | 17 | 13-class trigger panel + n_triggers + screen time + menstrual cycle |
+| Acute treatment | 12 | 11-agent panel, class, dose, time-to-treat, pain-free/relief 2hr, rescue, MOH |
+| Preventive treatment | 12 | 11-agent panel, class, dose, MMD reduction, 50/75% responder, adherence, discontinuation |
+| Disability/QoL | 14 | MIDAS, HIT-6, SF-12 PCS/MCS, PHQ-9, GAD-7, PSQI, work loss, productivity, cost |
+| Biomarkers | 8 | plasma CGRP, ictal flag, serotonin, cortisol, magnesium, inflammatory, autonomic |
+
+---
+
+## Calibration sources
+
+Every distribution is anchored to **named clinical references**. The
+headline anchors are **AMPP** (American Migraine Prevalence and Prevention
+Study), **CaMEO** (Chronic Migraine Epidemiology and Outcomes Study),
+and the four pivotal **CGRP mAb trials** (STRIVE / HALO / EVOLVE /
+PROMISE-2). Other anchors:
+
+- **ICHD-3 Diagnostic Criteria (Headache Classification Committee 2018)** —
+  6-class headache subtype taxonomy.
+- **AMPP Study (Bigal 2008 + Lipton 2007)** — US migraine prevalence,
+  triggers, demographics.
+- **CaMEO Study (Buse 2013 + Lipton 2014)** — chronic migraine
+  epidemiology, longitudinal outcomes.
+- **STRIVE Trial (Goadsby 2017 NEJM)** — Erenumab Phase 3, MMD reduction,
+  50% responder rate.
+- **HALO-EM/CM Trials (Silberstein 2017 NEJM)** — Fremanezumab Phase 3.
+- **EVOLVE-1/2 Trials (Stauffer 2018 JAMA)** — Galcanezumab Phase 3.
+- **PROMISE-2 Trial (Lipton 2020 Neurology)** — Eptinezumab Phase 3.
+- **ACHIEVE-I/II Trials** — Ubrogepant Phase 3 (acute gepant).
+- **Bigal 2006 Neurology** — Obesity-migraine bidirectional risk.
+- **Edvinsson 2018 Cephalalgia + Goadsby 1990** — Plasma CGRP biomarker
+  norms.
+- **Cernuda-Morollón 2013** — Chronic migraine CGRP elevation.
+- **Mauskop 2012 Headache + Welch 2001** — Magnesium-migraine link.
+- **Lipton 2014** — AMPP trigger frequency study.
+- **Ferrari 2001 Lancet** — Triptan efficacy meta-analysis.
+
+---
+
+## Validation scorecard
+
+The wrapper ships a 10-metric AMPP/CaMEO/CGRP-trial-anchored scorecard
+(`validation_scorecard.json`) that re-scores the dataset on every
+generation. Default seed 42 result:
+
+| ID | Metric | Target | Observed | Source |
+|---|---|---|---:|---|
+| M01 | Chronic Migraine Share | 0.15–0.25 | **0.199** | **ICHD-3 / AMPP** |
+| M02 | Episodic Migraine HDM Mean | 3–8 | **4.70** | **CaMEO (Buse 2013)** |
+| M03 | Chronic Migraine HDM Mean | 14–22 | **18.39** | **ICHD-3 (≥15)** |
+| M04 | Pain Intensity NRS Mean | 5–8 | **6.33** | AMPP + CaMEO |
+| M05 | CGRP mAb MMD Reduction | 2.5–4.5 days | **3.71** | **STRIVE / HALO / EVOLVE / PROMISE-2** |
+| M06 | Plasma CGRP Mean | 40–110 pg/mL | **54.97** | Edvinsson 2018 + Cernuda-Morollón |
+| M07 | Obesity (Chronic Migraine) | 0.20–0.40 | **0.275** | **Bigal 2006 Neurology** |
+| M08 | Magnesium Deficiency | 0.30–0.60 | **0.430** | Mauskop 2012 / Welch 2001 |
+| M09 | Stress Trigger Reported | 0.60–0.90 | **0.803** | AMPP (Lipton 2014) |
+| M10 | Female Patient Share | 0.62–0.82 | **0.690** | AMPP / GBD Migraine 2019 |
+
+**Grade: A+ (100/100). Verified across seeds 42, 7, 123, 2024, 99, 1.**
+
+**Standout calibration**: M01 chronic migraine share lands within
+0.13 percentage points of the ICHD-3 / AMPP 20% target. **M05 CGRP mAb
+MMD reduction (3.71 days) lands within 0.21 days of the STRIVE / HALO /
+EVOLVE / PROMISE-2 pooled mean of 3.5 days** — the exact CGRP-era
+clinical efficacy benchmark. M03 chronic migraine HDM (18.39) lands
+directly in the ICHD-3 ≥15 range center.
+
+---
+
+## Suggested use cases
+
+- **CGRP-era treatment-response modeling** — patient features +
+  preventive class → MMD reduction prediction with STRIVE-calibrated
+  CGRP mAb response.
+- **ICHD-3 subtype classification** — 6-class headache subtype ML from
+  symptom + aura + duration features.
+- **Disability outcome forecasting** — MIDAS + HIT-6 prediction from
+  baseline features and treatment regimen.
+- **Trigger-pattern ML** — 13-trigger feature space × headache_days_per_month
+  for trigger-impact modeling.
+- **Aura subtype detection** — visual aura sub-typing (scintillating
+  scotoma vs fortification spectra vs blurred vision) from prodrome +
+  duration features.
+- **CGRP biomarker validation** — plasma CGRP × headache_subtype ×
+  treatment_class × MMD outcome for biomarker development.
+- **Medication overuse headache (MOH) risk modeling** — acute
+  medication frequency + class × MOH progression prediction.
+- **AMPP / CaMEO comparable cohort analytics** — for healthcare data
+  scientists building published-study-comparable models without IRB
+  registry access.
+- **Health economics / HEOR** — work_days_lost + productivity +
+  annual_migraine_cost_usd for migraine cost-effectiveness modeling.
+- **Migraine + comorbidity multi-modal** — anxiety / depression /
+  fibromyalgia / sleep_disorder co-occurrence ML.
+
+---
+
+## Loading
+
+```python
+from datasets import load_dataset
+
+ds = load_dataset(
+    "xpertsystems/hcneu006-sample",
+    data_files="HC_NEU_006_dataset.csv",
+    split="train",
+)
+```
+
+Or with pandas directly:
+
+```python
+import pandas as pd
+from huggingface_hub import hf_hub_download
+
+path = hf_hub_download(
+    repo_id="xpertsystems/hcneu006-sample",
+    filename="HC_NEU_006_dataset.csv",
+    repo_type="dataset",
+)
+df = pd.read_csv(path)
+```
+
+The dataset ships with `HC_NEU_006_schema.json` providing per-column
+dtypes for pipeline integration:
+
+```python
+import json
+schema = json.load(open("HC_NEU_006_schema.json"))
+# {"patient_id": "object", "headache_subtype": "object", "headache_days_per_month": "int64", ...}
+```
+
+Cross-sectional, one row per patient — like HC-NEU-003 (Epilepsy) and
+HC-NEU-005 (Stroke). For longitudinal trajectory analysis on individual
+patients, use the full product which carries 24-month monthly diary
+sub-records.
+
+---
+
+## Schema highlights
+
+**Demographics** — `patient_id`, `headache_subtype` (6-class ICHD-3),
+`sex`, `age_at_baseline`, `race_ethnicity`, `education_years`,
+`geographic_region`, `bmi`, `obesity_flag`.
+
+**Comorbidities (10 flags)** — anxiety, depression, fibromyalgia,
+sleep_disorder, hypertension, OCP_use, psychiatric_medication, prior_er_visit,
+headache_specialist.
+
+**Headache characterization** — `headache_days_per_month`,
+`migraine_days_per_month`, `headache_duration_hours`, `pain_intensity_nrs`
+(0-10), `pain_location`, `pain_character` (Throbbing/Pulsating/Pressing/
+Stabbing), `aggravation_by_activity`, `nausea_flag`, `vomiting_flag`,
+`photophobia_flag`, `phonophobia_flag`, `osmophobia_flag`,
+`allodynia_score_asc12`, `cutaneous_allodynia_flag`,
+`chronification_risk_score`.
+
+**Prodrome/aura** — `prodrome_flag`, `prodrome_duration_hours`,
+`prodrome_symptoms`, `aura_flag`, `aura_type`, `aura_duration_minutes`,
+`visual_aura_subtype` ∈ {Scintillating_Scotoma, Fortification_Spectra,
+Blurred_Vision, NaN}, `spreading_depression_proxy`, `postdrome_flag`,
+`postdrome_duration_hours`, `postdrome_symptoms`.
+
+**Triggers (13-class)** — stress, sleep_disruption, hormonal,
+weather_barometric, skipped_meals, bright_light, strong_odors,
+dehydration, alcohol, caffeine_withdrawal, dietary_tyramine,
+physical_exertion, screen_time + `n_triggers_reported`,
+`trigger_reliability_score`, `menstrual_cycle_day`,
+`perimenstrual_attack_flag`.
+
+**Acute treatment** — `acute_treatment_name` (11 agents),
+`acute_treatment_class` ∈ {NSAID, Triptan, Gepant, Dittan, Ergotamine,
+Analgesic, None}, `acute_dose_mg`, `time_to_treat_hours`,
+`pain_free_2hr_flag`, `pain_relief_2hr_flag`,
+`most_bothersome_symptom_relief`, `sustained_pain_free_24hr`,
+`rescue_medication_flag`, `medication_overuse_days`,
+`medication_overuse_headache_flag`, `treatment_satisfaction_score`.
+
+**Preventive treatment** — `preventive_medication` (11 agents),
+`preventive_class` ∈ {BetaBlocker, AED, TCA, CGRP_mAb, CGRP_Gepant,
+Botox, None}, `preventive_dose_mg`, `botox_units`,
+`preventive_duration_months`, `preventive_adherence_pct`,
+`monthly_mmd_reduction`, `responder_50pct_flag`, `responder_75pct_flag`,
+`cgrp_mechanism_flag`, `preventive_discontinuation_flag`,
+`discontinuation_reason`.
+
+**Disability/QoL** — `midas_score`, `midas_grade` ∈ {Grade_I (0-5),
+Grade_II (6-10), Grade_III (11-20), Grade_IV (≥21)}, `hit6_score`
+(36-78), `promis_pain_interference_t`, `work_days_lost_per_month`,
+`presenteeism_days_per_month`, `global_productivity_loss_pct`,
+`sf12_pcs`, `sf12_mcs`, `phq9_score` (0-27), `gad7_score` (0-21),
+`psqi_score`, `caregiver_burden_score`, `healthcare_visits_per_year`,
+`annual_migraine_cost_usd`.
+
+**Biomarkers** — `plasma_cgrp_pg_ml`, `plasma_cgrp_ictal_flag`,
+`cgrp_response_index`, `plasma_serotonin_ng_ml`, `cortisol_am_ug_dl`,
+`magnesium_serum_mg_dl`, `magnesium_deficiency_flag`,
+`inflammatory_index`, `autonomic_dysfunction_score`.
+
+---
+
+## Calibration notes & limitations
+
+In the spirit of honest synthetic data, a few things buyers of the sample
+should know:
+
+1. **Generator bug fix applied: missing `obesity_flag` column.** The
+   upstream generator's `generate_comorbidities()` does not create
+   `obesity_flag`, but `generate_headache_baseline()` references it.
+   The wrapper monkey-patches `generate_comorbidities` to add
+   `obesity_flag` with Bigal 2006-calibrated prevalence (CM ~30%,
+   EM/TTH ~20%). Underlying generator file unmodified. Without this
+   patch, the generator crashes with KeyError.
+
+2. **Pain-relief 2hr = 100% and rescue medication = 100% are generator
+   quirks.** The upstream `generate_acute_treatment()` module sets
+   these flags as constants rather than sampling from the
+   `pain_free_2hr` rate dictionary. **Treat the
+   `pain_relief_2hr_flag`, `rescue_medication_flag` columns as
+   placeholders** until the full product release. The scorecard does
+   NOT validate these. For acute treatment efficacy ML, use the
+   `acute_treatment_class` field and reference Ferrari 2001 published
+   rates externally.
+
+3. **CGRP mAb 50% responder = 100% is a generator quirk.** Same root
+   cause as above — `responder_50pct_flag` is set deterministically
+   rather than sampled from the trial-anchored response rate. STRIVE /
+   HALO / EVOLVE / PROMISE-2 trials report 41-62% 50% responder rates
+   for CGRP mAbs vs ~25-30% placebo. The scorecard validates
+   `monthly_mmd_reduction` (which IS correctly calibrated, M05) as
+   the primary CGRP mAb efficacy metric.
+
+4. **Anxiety = 100% and depression = 0% are generator quirks.** The
+   `rng_bool()` helper uses `np.random.random()` (module-level) while
+   the broader codebase passes `rng` for seeded reproducibility. This
+   creates inconsistent state. **Do not use the
+   `anxiety_disorder_flag` or `depression_flag` columns directly for
+   comorbidity prevalence work.** For psychiatric comorbidity ML, use
+   the `phq9_score` (continuous, 0-27) and `gad7_score` (continuous,
+   0-21) columns instead.
+
+5. **Severe HIT-6 (≥60) is 2.8%** vs clinical expectations of 30-50%.
+   The HIT-6 distribution in this sample is shifted lower than expected
+   for a migraine clinical cohort. For HIT-6 modeling, validate the
+   raw distribution before training.
+
+6. **Fibromyalgia flag = 0% is a generator quirk.** Same `rng_bool`
+   inconsistency. For migraine-fibromyalgia comorbidity ML, the full
+   product fixes this.
+
+7. **Preventive discontinuation = 0% is unrealistic.** Real-world CGRP
+   mAb 1-year discontinuation rates are 30-50% (Hepp 2020, Nahas
+   2020). Generator does not model discontinuation; the full product
+   does.
+
+8. **Plasma CGRP varies bimodally by seed (55 to 96 pg/mL means).**
+   The generator's CGRP distribution mixes interictal (~30-50) and
+   ictal (~70-110) modes. The scorecard tolerance (35 pg/mL) spans
+   both modes; for ictal-only or interictal-only analysis, filter on
+   `plasma_cgrp_ictal_flag`.
+
+9. **MIDAS grade label is `Grade_I/II/III/IV`** (not the literature
+   convention `I_None/II_Mild/III_Moderate/IV_Severe`). Grade IV =
+   MIDAS ≥21 = severe disability per ICHD-3.
+
+10. **Deterministic seeding.** Wrapper passes user-specified seed
+    into `CONFIG["seed"]` and `np.random.seed()`. Seed sweep verifies
+    Grade A+ across {42, 7, 123, 2024, 99, 1}.
+
+---
+
+## Commercial / full product
+
+The full **HC-NEU-006** product covers 10,000 patients with calibrated
+CGRP mAb 50% responder rates per STRIVE/HALO/EVOLVE/PROMISE-2 (not
+deterministic 100%), realistic acute-treatment pain-free 2hr response
+sampling per Ferrari 2001 meta-analysis, fixed psychiatric comorbidity
+sampling, preventive discontinuation modeling per Hepp 2020 / Nahas
+2020 real-world data, 24-month monthly diary sub-records for
+longitudinal analysis, configurable cohort enrichment (chronic-only,
+pediatric, cluster headache, MOH, perimenstrual migraine), and
+patient-level outcome modeling. Available under commercial license —
+contact [pradeep@xpertsystems.ai](mailto:pradeep@xpertsystems.ai).
+
+XpertSystems.ai also publishes synthetic data products across Oil & Gas
+(17 SKUs), Cybersecurity, Insurance & Risk, and Materials & Energy.
+Catalog: [huggingface.co/xpertsystems](https://huggingface.co/xpertsystems).